List view / Grid view
19 January 2015 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...
19 January 2015 | By Public Health England press office
10-point action plan aims to eradicate TB across England...
19 January 2015 | By Public Health England Press Office
All appropriate public health actions taken to support individuals and protect public health...
16 January 2015 | By GlobalData
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData...
The British Generic Manufacturers Association will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Tuesday, February 24th...
16 January 2015 | By Roche
Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France...
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
15 January 2015 | By BIOTRONIK
Trial to demonstrate efficacy of AlCath Flux eXtra gold ablation catheter in Reducing the incidence of harmful Thromboemboli...
14 January 2015 | By GlobalData
Denmark’s pharmaceutical market will decline in value from $3.5 billion in 2013 to $3 billion by 2020, with price-cap agreements and high tax rates on pharmaceutical products two of the largest barriers to growth, according to research and consulting firm GlobalData...
14 January 2015 | By GlobalData
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData...
14 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299)...
13 January 2015 | By kdm communications
Dolomite’s droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair™ technology...
13 January 2015 | By Frost and Sullivan
Oncology, autoimmune and infectious diseases/vaccines are hot areas for novel therapeutics and in vitro diagnostics in 2015...
13 January 2015 | By eyeforpharma
Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma...
13 January 2015 | By Porter Novelli Limited
Roche welcomes the announcement from NHS England that patients can continue to access our breast cancer medicines Perjeta, Kadcyla and Avastin via the Cancer Drugs Fund (CDF), but is extremely disappointed that patients with advanced bowel and ovarian cancer will now be denied Avastin on the NHS, following their review…
